Full Text Inquiry
ePub [ahead of print] Inquiry Form:

Thank you for your interest in the full text of this ePub article. The full text of this article is not available as yet. Could you please complete and submit the brief EPub full text inquiry form given below and one of our representatives will contact you shortly with details of the article, it's availability, and price on order.


Article Detail:

Title:
Dihydroartemisinin and its Analogs: A New Class of Antitubercular Agents

Abstract:
Tuberculosis (TB) is one of the leading causes of mortality worldwide. Resistance against the frontline anti-tubercular drugs has worsened the already alarming situation, which requires intensive drug discovery to develop new, more effective, affordable and accessible anti-tubercular agents possessing novel modes of action. Dihydroartemisinin, a metabolite of artemisinin was semi-synthesized into 8 acyl (DHA-2 – DHA-9) derivatives and were evaluated for anti-tubercular potential against H37Rv virulent strain of Mycobacterium tuberculosis by agar-based proportion assay. Results show that all the derivatives were active but out of eight, 12-O-m-anisoyl DHA-5 and 12-O-p-anisoyl DHA-6 (MIC 25.0 µg/mL) showed promising activities. Further, the synergistic activity was studied between DHA-5 and front-line anti-TB drugs, Isoniazid (INH) and Rifampicin (RFM), which showed reduction in MIC to with the derivative (by 1/8th, i.e. 3.12 µg/mL and that of RFM by ¼th, i.e. 0.05 µg/mL). The sum -fractional inhibitory concentration (Σ FIC) was 0.375. These results suggest a synergistic effect of the DHA-5 with RFM. Therefore, these compounds have potential for anti-tubercular drug development from an in-expensive and non-toxic natural product. To the best of our knowledge this is the first ever report on the anti-tubercular potential of DHA and its derivatives.

Journal Title: Current Topics in Medicinal Chemistry

Price: $95


Inquiry Form

5 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.